Biohaven Pharma (BHVN) Tops Q2 EPS by 6c, Revenues Beat

Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($2.55), $0.06 better than the analyst estimate of ($2.61). Revenue for the quarter came in at $9.7 million versus the consensus estimate of $7.65 million.

Vlad Coric, M.D. Chief Executive Officer, commented, "This has been an unprecedented quarter in so many ways. We are pleased to report the Company is excelling in achieving our goals across multiple areas: the launch trajectory of Nurtec ODT is exceeding initial expectations with net sales in the second quarter of $9.7M; we continue to make progress in advancing our clinical trials and have a robust pipeline; and the strategic financing of up to $950M dollars that we announced on Friday puts us in a strong financial position to execute on our long-term growth plans. Biohaven has a strong portfolio of product opportunities and we believe one of the most promising neuroscience pipelines. We are in a strong position to grow the global value of our CGRP targeting franchise, and we will continue to focus on our R&D efforts on delivering best-in-class therapies for patients suffering from neurologic and neuropsychiatric disorders."

For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• Delta Air Lines: demand remains strong despite global uncertainty
• Fairfax prices $750 million senior notes offering at 6.200% interest